The satiety produced by amylin analogues tends to reduce caloric intake without the extreme food aversion that sometimes occurs with high-dose GLP-1 agonists, which can lead to inadequate protein intake and subsequent muscle loss
Ibuprofen can also impact kidney function and cardiovascular health, necessitating caution and medical supervision, especially in patients with preexisting conditions
Although research on AOD 9604 is ongoing, preliminary studies suggest its efficacy in inducing weight reduction
The FDA does not review compounded medications for safety, effectiveness, or quality prior to dispensing
The concept of microdosing with GLP-1 agonists describes a treatment strategy in which only a fraction of the usual therapeutic dose, typically 5% to 25%, is administered, often via individually compounded prescriptions and at longer intervals